NeuroCog Trials, Inc. announces that a new method has been established for reviewing administration procedures and data collection for the Alzheimer’s Disease Assessment Scale (ADAS-Cog). This method will be utilized by a large pharmaceutical company for a new clinical trial testing the safety and efficacy of a novel treatment for mild-to-moderate Alzheimer’s Disease.
Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, said, “There have been a lot of disappointments in Alzheimer’s Disease trials over the past few years. We feel that our new method, which involves video and audio recording of assessment sessions, can increase the reliability of assessments and has the potential to increase sensitivity to real treatment effect.”
The forthcoming trial will assess several hundred patients at several different time points with the ADAS-Cog and interview-based rating scales. Dr. Keefe added, “We applaud our colleagues in the pharmaceutical industry who are enthusiastic to adopt innovative new methodologies for assessing change in clinical trials. We also admire the raters and investigators who have demonstrated great excitement over being able to use the latest advances in assessment methodology.”